These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11988280)

  • 1. Priority-setting decisions for new cancer drugs.
    Millar A
    Lancet; 2002 Apr; 359(9316):1524; author reply 1524-5. PubMed ID: 11988280
    [No Abstract]   [Full Text] [Related]  

  • 2. Priority-setting decisions for new cancer drugs.
    Wheatley K; Djulbegovic B; Glasmacher A
    Lancet; 2002 Apr; 359(9316):1525. PubMed ID: 11988282
    [No Abstract]   [Full Text] [Related]  

  • 3. Priority-setting decisions for new cancer drugs: a qualitative case study.
    Martin DK; Pater JL; Singer PA
    Lancet; 2001 Nov; 358(9294):1676-81. PubMed ID: 11728542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expediting the availability of drugs for US patients with cancer.
    Farrell AT; Pazdur R; von Eschenbach AC
    Nat Clin Pract Urol; 2008 Dec; 5(12):654-6. PubMed ID: 19050708
    [No Abstract]   [Full Text] [Related]  

  • 5. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
    Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
    Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I-SPY 2 may change how clinical trials are conducted: researchers aim to accelerate approvals of cancer drugs.
    Printz C
    Cancer; 2013 Jun; 119(11):1925-7. PubMed ID: 23695808
    [No Abstract]   [Full Text] [Related]  

  • 7. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
    Schilsky RL
    J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
    [No Abstract]   [Full Text] [Related]  

  • 8. The ODAC Chronicles: Part 6a. ODAC's structure and function.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):573-7. PubMed ID: 16111457
    [No Abstract]   [Full Text] [Related]  

  • 9. Are european cancer patients getting a fair deal?
    McVie JG
    Ann Oncol; 2001 Aug; 12(8):1033-5. PubMed ID: 11583176
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety Profiles and Pharmacovigilance Considerations for Recently Patented / Approved Anticancer Drugs.
    Baldo P
    Recent Pat Anticancer Drug Discov; 2019; 14(3):202. PubMed ID: 31778105
    [No Abstract]   [Full Text] [Related]  

  • 11. [Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies].
    Ludwig WD; Schildmann J
    Onkologie; 2011; 34 Suppl 1():6-10. PubMed ID: 21389762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding.
    Sinclair S; Hagen NA; Chambers C; Manns B; Simon A; Browman GP
    Health Policy; 2008 May; 86(2-3):381-90. PubMed ID: 18243395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 clinical trials nursing: determining safety and side effects on the road approval.
    Lindberg D
    ONS Connect; 2012 Jul; 27(7):10-4. PubMed ID: 22855983
    [No Abstract]   [Full Text] [Related]  

  • 14. Tissue-agnostic cancer drug pipeline grows, despite doubts.
    Garber K
    Nat Rev Drug Discov; 2018 Apr; 17(4):227-229. PubMed ID: 29520093
    [No Abstract]   [Full Text] [Related]  

  • 15. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?
    Laupacis A
    CMAJ; 2002 Jan; 166(1):44-7. PubMed ID: 11800247
    [No Abstract]   [Full Text] [Related]  

  • 16. The second wave in kinase cancer drugs.
    Garber K
    Nat Biotechnol; 2006 Feb; 24(2):127-30. PubMed ID: 16465146
    [No Abstract]   [Full Text] [Related]  

  • 17. Swimming upstream: an advocate reflects on cancer research and social realities.
    Mayer M
    J Clin Oncol; 2008 Jun; 26(16):2783-6. PubMed ID: 18509190
    [No Abstract]   [Full Text] [Related]  

  • 18. [Does oncology change its paradigm? The challenge of agnostic approval of new therapies.].
    Martini N
    Recenti Prog Med; 2018 Jun; 109(6):317-318. PubMed ID: 29968857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing Accelerated Approval for Drugs With Accelerated Withdrawal.
    Braillon A; Menkes DB
    JAMA Intern Med; 2016 Apr; 176(4):566-7. PubMed ID: 27043114
    [No Abstract]   [Full Text] [Related]  

  • 20. Balancing Accelerated Approval for Drugs With Accelerated Withdrawal--Reply.
    Kim C; Prasad V
    JAMA Intern Med; 2016 Apr; 176(4):567. PubMed ID: 27043117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.